Silver Book Fact

TAVR Success in sSAS Patients

A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable, and 1.1% for those at intermediate surgical mortality risk.

Early Clinical and Echocardiographic Outcomes After SAPIEN 3 Transcatheter Aortic Valve Replacement in Inoperable, High-Risk and Intermediate-Risk Patients with Aortic Stenosis. Eur Heart J. 2016; 37: 2252-62. https://academic.oup.com/eurheartj/article/37/28/2252/2237654/Early-clinical-and-echocardiographic-outcomes

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Disease specific status and generic health status improvements from TAVR and SAVR
    Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in intermediate risk symptomatic aortic stenosis (SAS) patients were associated with significant improvements in disease specific status (16 to…  
  • Cost-effectiveness of SAVR
    The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).  
  • Cost-effectiveness of TAVR in sSAS patients
    Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…  
  • TAVR Success in sSAS Patients
    A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable,…  
  • From approval in 2011 through 2015 >54,000 TAVRs were performed in 418 centers in 48 states